• Eligible patients: salvage intensive re-induction therapy • Non-eligible patients: and if non-proliferative AML, consider hypomethylating agents (±Venetoclax) • Consider starting HU in proliferative AML • Targeted therapy (anti FLT3 or IDH1/2) should be given • G-CSF and transfusion as for induction. This evidence concerns the gene CSF3 and acute myeloid leukemia.